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Abstract
Background and Aims: Success in delivering value-based healthcare involves measuring outcomes 
that matter most to patients. Our aim was to develop a minimum Standard Set of patient-centred 
outcome measures for inflammatory bowel disease [IBD], for use in different healthcare settings.
Methods: An international working group [n  =  25] representing patients, patient associations, 
gastroenterologists, surgeons, specialist nurses, IBD registries and patient-reported outcome 
measure [PROM] methodologists participated in a series of teleconferences incorporating a 
modified Delphi process. Systematic review of existing literature, registry data, patient focus 
groups and open review periods were used to reach consensus on a minimum set of standard 
outcome measures and risk adjustment variables. Similar methodology has been used in 21 other 
disease areas [www.ichom.org].
Results: A minimum Standard Set of outcomes was developed for patients [aged ≥16] with IBD. 
Outcome domains included survival and disease control [survival, disease activity/remission, 
colorectal cancer, anaemia], disutility of care [treatment-related complications], healthcare 
utilization [IBD-related admissions, emergency room visits] and patient-reported outcomes 
[including quality of life, nutritional status and impact of fistulae] measured at baseline and at 
6 or 12  month intervals. A  single PROM [IBD-Control questionnaire] was recommended in the 
Standard Set and minimum risk adjustment data collected at baseline and annually were included: 
demographics, basic clinical information and treatment factors.
Conclusions: A Standard Set of outcome measures for IBD has been developed based on evidence, 
patient input and specialist consensus. It provides an international template for meaningful, comparable 
and easy-to-interpret measures as a step towards achieving value-based healthcare in IBD.
Key Words:  Inflammatory bowel disease; patient reported outcomes; quality improvement
1. Introduction
A paradigm change is happening in healthcare. Many healthcare 
organizations are embracing value-based healthcare,1–4 an approach 
that aims to achieve the best possible health outcomes for the lowest 
cost.5,6 According to the framework presented by Porter et al.,7 the 
key to determining “value” is measuring outcomes that matter most 
to patients. When providers are asked to report outcomes, perform-
ance improves,1 even when those outcomes are not patient-defined. 
Outcome measurement [in contrast to more familiar measures of the 
care-delivery process5,6] has the potential to direct resources towards 
strategies with the highest value, which is particularly relevant for 
chronic diseases that are major drivers of healthcare costs.8 For com-
plex conditions such as inflammatory bowel disease [IBD], the poten-
tial gain from a value-driven healthcare strategy could be even greater 
than conditions with defined interventions, such as cataract surgery.9
Crohn’s disease [CD] and ulcerative colitis [UC], collectively 
known as IBD, disproportionately affect young adults in their educa-
tionally and economically productive years, leading to reduced qual-
ity of life, social functioning and productivity,10–13 often requiring 
lifelong drug treatment or major surgery.14,15 This accounts for high 
costs to the healthcare system and society,10,16,17 with annual direct 
healthcare costs in Europe alone estimated at 4.6–5.6 billion Euros, 
and a global rise in burden, particularly in East Asia.12,18–20 Despite 
the potential impact on the individual, no patient-reported outcome 
measures [PROMs] are used in routine practice, so patient-reported 
outcomes [PROs], other than disease-related symptoms, are rarely 
captured. Furthermore, there remains widespread variation in clin-
ical practice and quality of care provided to patients with IBD.21–23 
With the exception of collaborations such as the ImproveCareNow 
network,24–26 current IBD registries track different outcomes or 
similar outcomes with different definitions, making meaningful 
comparisons between populations difficult.27 Similarly, no ‘core out-
come sets’ are currently available for IBD clinical trials to date, limit-
ing the ability for direct comparison or combining of results.28
To align outcome measurement in IBD as a step towards value-
driven care, the Oxford Academic Health Science Network col-
laborated with International Consortium for Health Outcomes 
Measurement [ICHOM] to form an IBD Working Group of clin-
ical and outcome specialists, patients and their associations [Crohn’s 
& Colitis Foundation of America, CCFA; Crohn’s & Colitis UK, 
CCUK; and Association François Aupetit, AFA] from 12 countries. 
ICHOM is a non-profit organization founded in 2012 by Michael 
Porter of Harvard Business School, the Boston Consulting Group 
and the Karolinska Institutet [www.ichom.org], that aims to drive 
quality improvement and reduce variation in standards between 
healthcare providers through outcome measurement. This has 
resulted [as of  2017] in 21 Standard Sets of outcomes for differ-
ent medical conditions that are being implemented in practice.29–35 
The advantage of this collective effort is that all use standardized 
methodology; consequently, each condition becomes part of a wider 
whole for introducing outcome measurement into routine practice, 
facilitating implementation when different disease areas can learn 
from others.
Our goal was to develop a minimum Standard Set of patient-cen-
tred outcomes for IBD to provide a common language for outcomes 
that can be tracked systematically.
2. Materials and Methods
2.1. Context and overview
The Standard Set for patients with IBD [age ≥16 years] aims to pro-
vide a template with meaningful, comparable and easy-to-interpret 
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measures that can be implemented in any healthcare setting to track 
and compare outcomes. It represents a ‘minimum’ standard to cover 
the cycle of care for both CD and UC and tracks health status 
[Figure 15], while not precluding collection of additional measures.
Selection principles for outcomes were:
[i] feasible to capture in routine clinical practice;
[ii] the end results of care, not the process of care;
[iii] important to patients with IBD; and
[iv] responsive to change.
Four domains [Survival and Disease Control; Symptoms, Function, 
and Quality of Life; Disutility of Care; and Healthcare Utilization] 
were pre-specified, but not the number of measures. For PROMs, 
considerations included domain coverage and psychometric prop-
erties.36,37 In the selection of the PROM tool, we aimed to capture 
health status and impact on quality of life beyond specific disease-
related symptoms, using a validated instrument applicable to both 
CD and UC. Time points for data collection were determined by 
considering these principles and the burden of data capture on the 
patient or provider.
Case-mix variables for risk adjustment were selected by: [i] the 
relevance [strength of causal linkage between the characteristic and 
the outcome]; [ii] independency; [iii] practicality; and [iv] compar-
ability at a global level.
2.2. The Project Team and Working Group
The Project Team comprised a Chair [ST], an ICHOM Project 
Leader [CR], and a Research Fellow [AK] responsible for co-ordinat-
ing a series of teleconferences and the consensus process. Material 
for discussion at each call was jointly prepared by the Project Leader 
and the Research Fellow, who reviewed available registry data and 
evidence from scientific literature. The Project Team invited patient 
associations to recommend patients or representatives and identified 
internationally recognized specialists. In accordance with standard 
ICHOM criteria, final selection of Working Group members consid-
ered [i] expertise, as evidenced by publications on patient outcomes, 
invitation to speak at international conferences, or national-level 
leader status, [ii] representation of different geographical areas and 
areas of expertise, [iii] availability in terms of being able to partici-
pate in discussions during teleconferences, and [iv] having no con-
flict of interest that could compromise the neutrality of the Standard 
Set. The resulting Working Group [n  =  25, see author list] repre-
sented seven specialties or interest groups [patients, gastroenterolo-
gists, surgeons, specialist nurses, IBD registries, PROM methodology 
specialists and representatives of large patient organizations] from 
12 countries [Australia, Belgium, Brazil, Canada, China, France, 
Germany, India, Netherlands, South Korea, UK and USA].
2.3. Consensus Process
A systematic literature review to identify IBD-related outcomes, 
relevant definitions and measurement tools of electronic databases 
[Medline, EMBASE, PsychInfo, Cumulative Index to Nursing and 
Allied Health Literature, Allied and Complementary Medicine, 
University of Oxford PROM bibliography database to 2005, and the 
Cochrane Library] was undertaken. The search strategy was delib-
erately chosen to capture all studies that reported on any clinical or 
patient-reported outcomes [including instruments used to measure 
them] for IBD, without restricting the search to specific domains or 
a specific time frame, although it was limited to randomized con-
trolled trials, reviews, and meta-analyses published in English [see 
Supplementary Material 1, which can be found at Journal of Crohn’s 
and Colitis Online]. This was supplemented by manual searching of 
references from key journals that included published IBD guidelines 
and reviews of IBD-related outcomes. The group convened eight 
teleconferences and seven online surveys incorporating a modified 
two-round Delphi process38 to reach consensus based on evidence 
and specialist opinion between October 2015 and July 2016. Before 
each teleconference, the Project Team circulated an agenda, list of 
key proposals and relevant evidence from the literature for review 
[where relevant outcomes and metrics were organized into summary 
tables using a defined hierarchy]. These were then used to generate 
the discussions, with all participants at each call contributing to key 
decisions.
Each teleconference was followed by minutes and an online 
survey for feedback and voting [from all Working Group members 
Survival
Degree of health achieved or maintained
Tier 1
Health Status
Achieved or
Retained
Tier 2
Process of
Recovery
Tier 3
Sustainability
of Health
Time to recovery and return to normal activities
Disutility of the care or treatment process
Sustainability of health / recovery and nature of recurrences
Recurrences
Care-induced
Illnesses
Long-term consequences of therapy
(e.g., diagnostic errors and ineffective care, treatment-related
discomfort, complications, or treatment errors)
(e.g., care-induced illnesses)
Figure 1. Michael Porter’s hierarchy of outcome measures.
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including non-participants of the call]. “Key decision areas” included: 
[i] the scope to be covered by the Standard Set [Calls 1 and 2, 1 sur-
vey]; [ii] items to be included in the Standard outcome set, includ-
ing definition, response options, data source, and timing of collection 
[Calls 2–5, 3 surveys]; and [iii] case-mix factors required for risk 
adjustment, including definition, response options, data source, and 
timing of collection [Calls 5–8, 3 surveys]. “Consensus” was prede-
fined as >70% of the voting Working Group members rating the item 
as very important [score of 7–9 on a 9-point Likert scale] in either 
voting round. The Project Team was excluded from voting, giving a 
maximum of 22 possible votes for each item. Results as percentage 
agreement were then made available to all Working Group members. 
Any items where consensus was not reached but ranked 7–9 by at 
least 50–70% of respondents were further discussed, followed by 
a second survey. Items ranked 7–9 by <50% of respondents were 
excluded from further surveys. Similarly, any newly introduced items, 
change in definition or timing of collection were subject to further 
surveys to reach consensus. All voted items were reviewed at the sub-
sequent teleconference, whether voted in or out as per pre-defined 
consensus definition, to provide an additional opportunity for any of 
the Working Group members to challenge or confirm their inclusion.
A “patient focus group”, including six IBD patients and two 
“1:1 patient interviews” were conducted39 by CR after the Working 
Group launch, to obtain patients’ perspectives on outcomes that 
matter most to them, using a structured interview and open-ended 
questions. Participants, nominated by CCUK and Crohn’s & Colitis 
Australia, discussed which outcomes were of greatest importance 
to them. The focus groups represented a mix of patients with CD 
or UC who had received a variety of surgical and/or medical treat-
ments with different healthcare utilization experiences. Additional 
1:1 interviews were undertaken for one man and one pregnant 
woman. Representatives of patient associations and other Working 
Group members shared their experience with other patient focus 
groups22,40–42 during teleconferences to confirm that the most import-
ant patient-reported outcome domains and patient concerns were 
represented in the Standard Set.
The resulting Standard Set was approved unanimously by the 
Working Group before being subject to “patient validation sur-
veys” and a period of “open review” by interested clinicians before 
finalization. The patient validation surveys involved circulation of 
the Standard Set to a geographically and culturally diverse group 
of patients, with the aid of multiple patient organizations, includ-
ing CCUK and Crohn’s & Colitis Australia, as well as local patient 
groups invited by Working Group members from Brazil, India and 
China [PK, RB, ZhR]. The survey was translated into French, Hindi, 
Brazilian Portuguese, and simplified Chinese. It was completed by 
318 patients representing a diverse age group and diverse geograph-
ical locations, with 83% indicating that they felt that the current 
Standard Set captured the most important outcomes that matter or 
have mattered to them [see Supplementary Material 2, which can 
be found at Journal of Crohn’s and Colitis Online]. A  web-based 
draft version of the Standard Set was made available to interested 
clinicians, ICHOM website registrants and other stakeholders for 
comment on the Standard Set before finalization.
3. Results
3.1. Scope: Patients with Inflammatory Bowel 
Disease
The agreed focus [75%, n = 16/20] was all patients [age ≥16 years] 
with IBD defined by the International Classification of Diseases, 
Tenth Revision, Clinical Modification [ICD-10-CM] diagnosis codes 
K50 [CD], K51 [UC] and K52.3 [IBD-Undetermined [IBD-U]]. 
Children [age <16 years] were excluded because PROMs derived for 
adults were potentially inapplicable and the Montreal classification 
of IBD43 uses this threshold, recognizing that transitional care for 
young people with IBD can begin as early as age 14.44–46 Other non-
infective causes of colitis in ICD-10 code K52 were excluded.
3.2. Systematic Review of IBD-related Outcomes 
and Measures
Using a defined hierarchy,5 outcomes and metrics were selected from 
565 papers and abstracts for the Working Group, which was further 
informed by registry databases and input from patient focus groups. 
In the four domains, 239 preliminary outcome measures were iden-
tified, from which 14 measures and their instruments were selected 
[see Supplementary Material 3 and 4, which can be found at Journal 
of Crohn’s and Colitis Online].
3.3. The Standard Set: Outcome Domains and 
Measures [Table 1]
3.3.1. Survival and Disease Control
Four measures were selected [Figure 2]. Although death attributable 
to IBD is infrequent, it is of overriding relevance to patients, high-
lighted by patient focus groups. Capturing overall survival allows the 
ultimate impact of care to be assessed. Recognizing the limitations of 
death registries and reporting in many countries, the Working Group 
voted [82%, n = 14/17] to include both “overall and IBD-specific sur-
vival”. The Working Group recommends tracking survival each year.
Control of “disease activity and remission” is one of the major 
goals of treatment. Defining remission, however, is not straightfor-
ward, and no agreed tool currently exists to capture disease activity, 
which in itself can be defined in many ways. There is often discrep-
ancy between the patient’s symptoms and their state of biological 
remission, so the Working Group considered these separately. The 
consensus [100%, n = 17/17] was to use the Manitoba IBD index 
[MIBDI]47 [Table 2] for both UC and CD at baseline and 6-monthly 
intervals. The MIBDI is a single-item, patient-defined disease activ-
ity measure reported on a 6-point Likert scale allowing a 6-month 
recall period. It has been validated against the Harvey–Bradshaw 
Index, the Powell–Tuck Index, and the Inflammatory Bowel Disease 
Questionnaire [IBDQ].48 The Working Group decided [88%, 
n = 16/18; 94%, n = 17/18] that the clinician should separately report 
clinical remission and biological remission, and document how bio-
logical remission was determined [biochemical, endoscopic, imaging].
“Colorectal cancer”, although infrequently complicating IBD,49 
was important to patient focus groups. The Working Group agreed 
[94%, n = 16/17], since treatment may alter this outcome. Annual 
tracking of a definitive diagnosis was recommended, and for affected 
patients, reporting whether colorectal dysplasia had previously been 
diagnosed, and whether they had been participating in colorec-
tal cancer surveillance. Surveillance details were considered to be 
beyond the scope of minimum standards.
“Anaemia”, defined by the World Health Organization [WHO],50 
was recommended [71%, n = 12/17] as an independent marker of 
disease activity and potentially modifiable outcome, tracked at base-
line and at 6-monthly intervals.
3.3.2. Healthcare Utilization
Two measures were selected [Figure  2]. Unplanned admissions 
or Emergency Department visits concern patients with IBD, since 
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they can imply suboptimal disease control, non-specialist care, or 
increased use of ionizing radiation [CT scans].22 To achieve a prac-
tical measure, the Working Group recommended [71%, n = 12/17] 
recording “the total number of emergency room visits every 
12  months” and “all IBD-related admissions requiring at least an 
overnight stay”, defined as planned or unplanned, and recording the 
total length of stay in days over a 12-month period.
3.3.3. Disutility of Care
Two measures were selected [Figure 2]. “Complications resulting from 
IBD-related treatment” are a central concern for patients that informs 
their choices about management. Attribution to disease or therapy is 
contentious, and determining severity is difficult. The Working Group 
recommended [76%, n  =  14/18] documenting a complication that 
occurred during or within 3 months of any treatment [medical, endo-
scopic, radiological, or surgical], separately recording the outcome [fur-
ther intervention, unplanned admission, or prolonged hospitalization].
Steroid dependency is a cause of morbidity in IBD, is a concern to 
patients and may reflect quality of care.51,52 The Working Group recom-
mended [82%, n = 14/17] documenting any systemic “steroid use” within 
the previous 12 months and whether the duration exceeded 3 months.
3.3.4. Symptoms, Function, and Quality of Life  
[Patient-Reported Outcomes35]
One tool was selected to cover five measures that matter to 
patients [“change in bowel symptoms”, “pain & discomfort”, 
“normal activities”, “energy & fatigue”, and “depression & anx-
iety”] [Figure  2]. The tool recommended [100%, n  =  20/20] was 
the IBD-Control Questionnaire,42 applied every 6 months. All IBD-
specific PROMs were examined by specialists within the Working 
Group [RF, WvD] for their conceptual and measurement designs, 
domain coverage and psychometric properties using ISOQOL cri-
teria [Table 3].36 Although the best established PROM in IBD is the 
Inflammatory Bowel Disease Questionnaire [IBDQ],48 it has failed 
to embed itself in clinical practice because of its length and need for 
a licence. The IBD-Control questionnaire42 captures disease control 
from the patient’s perspective using generic language and measur-
ing themes with which all patients with IBD can identify. It can be 
administered in less than a minute and has shown strong validity 
against the EQ-5D,53 the UK-IBDQ,54 the Harvey–Bradshaw Index55 / 
Simple Clinical Colitis Activity Index,56 and the Physician Global 
Assessment. For the purpose of the Standard Set, the Working Group 
selected Questions 1, 2 and 3 of the IBD Control Questionnaire to 
be included [Table 4], which adequately covered the five measures 
of interest.
“Nutritional status” and impact of “fistulae” [for patients with 
CD] were considered separately. No simple, responsive measure for 
either could be identified. The Working Group recommended [100%, 
n  =  19/19] recording “height and weight” at baseline as a surro-
gate marker for nutritional status, from which the Body Mass Index 
[BMI] can be calculated, then the change in weight at 6-monthly 
intervals. For fistulae, a single question on presence or absence of a 
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Figure 2. ICHOM Standard Set for Inflammatory Bowel Disease. 1IBD-Control Questionnaire [Q1–3]. 2 The Manitoba IBD Index.
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fistula [none, perianal, rectovaginal, enterocutaneous, or other] was 
added, to be completed at baseline and at 6-monthly intervals.
3.4. Case-mix Variables for Risk Adjustment
The Working Group defined a minimum set of patients’ baseline 
characteristics [Table 5] to enable comparisons of outcomes between 
centres, regions or countries to be placed in context. Selection had 
to be practical to capture in routine care, balancing the burden 
with the need for accurate comparisons. The categories of case-
mix variables included: “demographics” [year and sex at birth, 
education level, smoking status], baseline “clinical factors” [Self-
reported Comorbidity Questionnaire, SCQ,57 with specific inclusion 
of autoimmune conditions and previous infections with Human 
Immunodeficiency Virus, hepatitis B virus, or tuberculosis], baseline 
“condition factors” [diagnosis, date of diagnosis, disease phenotype 
using Montreal Classification,43 and presence of extra-intestinal 
manifestations categorized as eye, skin, joint, hepatobiliary or other], 
and “treatment factors” [current medication: no IBD drugs, steroids, 
biologics, immunomodulators, other; type of IBD-related surgery]. 
Demographics and baseline clinical factors will be patient-reported, 
while baseline condition and treatment factors will be clinician-
reported at baseline, and tracked annually as appropriate for smok-
ing status, disease location/behaviour and treatment.
4. Discussion
A “minimum” set of standardized outcome measures represents a 
common language that can be used across healthcare jurisdictions 
as a step towards value-driven care in IBD. Value-driven care relies 
on reporting and systematic tracking of patient-centred outcomes, 
allowing providers to compare meaningful outcomes for patients 
and to adopt strategies that achieve the best “value” for participat-
ing stakeholders. This work represents a first step. The performance 
characteristics of the measures need evaluating in real-world prac-
tice. If adopted and implemented, such an approach has the potential 
to reduce variations in practice and improve standards of care on a 
global scale.
Existing studies show wide variations in the quality and deliv-
ery of care in IBD and suggest significant potential for improve-
ment. National audit in the UK in 2006 led to the development 
of a set of IBD Standards that defined key performance indica-
tors and recommendations for quality, patient-centred care.23 
In the USA, a collaborative of paediatric IBD centres formed the 
ImproveCareNow network to develop an outcomes registry using 
a shared, prospective database between nearly 50 centres. Over 
Table 2. The Manitoba IBD Index.47
In the last 6 months, my disease has been
0 = Constantly active, giving me symptoms every day
1 = Often active, giving me symptoms most days
2 = Sometimes active, giving me symptoms on some days [for instance 
1–2 days/week]
3 = Occasionally active, giving me symptoms 1–2 days/month
4 = Rarely active, giving me symptoms on a few days in the past 
6 months
5 = I was well in the past 6 months: what I consider a remission or 
absence of symptoms
Table 1. ICHOM Standard Set for Inflammatory Bowel Disease.
Patient population Measure Supporting information Timing Suggested data sources
Symptoms, function, and quality of life
All patients Change in bowel symptoms Tracked via the IBD–Control Baseline and 
6-monthly
Patient-reported
Missing planned activities
Night symptoms
Pain or discomfort
Energy and fatigue
Feel anxious or depressed
Overall control over IBD
Weight N/A
All patients with Crohn’s 
Disease
Fistula symptoms
Disutility of care
All patients Steroid use Use of any systemic steroids within the 
previous 12 months
Baseline and annual 
follow-up
Clinician-reported
Occurrence and impact of 
complication from an IBD 
intervention
Including whether a complication occurred 
and the outcome of the complication
Healthcare utilization
All patients Time spent in hospital Including all IBD-related admissions 
requiring an overnight stay and  
emergency department visits
Baseline and annual 
follow-up
Clinician-reported
Survival and disease control
All patients Presence of anaemia Using WHO definitions Baseline and 
6-monthly
Clinician-reported
Disease activity and remission Tracked via the Manitoba IBD Index and 
additional clinician report
Patient and 
clinician-reported
Colorectal cancer Diagnosis of colorectal cancer and  
preceding colorectal dysplasia
Baseline and annual 
follow-up
Clinician-reported
Overall survival Date of death
Cause of death Death attributable to IBD or to an  
intervention for IBD
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the years, remission rates within the participating centres have 
increased from 55% to 75%, using the physician’s global assess-
ment.24 This highlights what can be achieved when the provision of 
care is driven by outcomes.
The Standard Set presented here is the first coordinated inter-
national, multidisciplinary effort to reach a precisely defined core set 
of outcomes for all adult patients with IBD. The development pro-
cess has followed reporting guidelines for core outcome sets.58 This 
is an advantage, because IBD becomes just one of many [21 diseases 
as of 2017, www.ichom.org] diseases subject to the same process. 
The final Standard Set [Figure 2] tracks 14 outcome measures that 
encompass the full cycle of care for both CD and UC, as well as 
health status beyond completion of care. The selection process was 
guided by careful consideration of the hierarchy of outcome meas-
ures and pre-specified domains. Each of the selected outcome meas-
ures was subject to voting on definition, response options and data 
source in a formal consensus process. Practicality in terms of burden 
on the patient and/or the provider, and feasibility in a broad range of 
healthcare settings were additional considerations.
Importantly, the Standard Set emphasizes outcomes that matter 
most to patients. The US Food and Drugs Administration has advo-
cated routine inclusion of PROs as co-primary endpoints in clinical 
trials.59 Although improving quality of life is a common secondary 
endpoint in clinical trials, it has been the primary endpoint in only 
one trial in IBD60 and is rarely captured in routine practice. While 
the IBDQ has been widely used in trials, it has failed to embed itself 
in routine practice because of its length, and pragmatic reasons of 
cost and administrative burden. A shorter version,61 and other more 
recent variations of the IBDQ such as the UK version of the IBDQ54 
and Crohn’s and Ulcerative Colitis Questionnaire62 have similarly 
failed to gain popularity. The IBD-Control Questionnaire,42 unani-
mously recommended by the Working Group, is a PROM tool devel-
oped with the primary aim of supporting patient-centred care in 
practice. It captures the patient’s perspective on disease control using 
Table 3. Domain coverage and psychometric properties of IBD-specific PROMs.
Domain coverage by IBD-specific PROMs
Outcome domains* IBDQ SIBDQ IBDQ-9 UK-IBDQ CUCQ-32 CUCQ-8 IBD-control RFIPC IBD-DI
Overall change in symptom status Partially No Partially No No No Yes No No
Abdominal pain / discomfort Yes Yes Yes Yes Yes Yes Yes Yes Yes
Bowel habit Yes No Yes Yes Yes No Indirectly No Yes
Rectal bleeding Yes No No Yes Yes No Indirectly No Yes
Tenesmus Yes Yes No Yes Yes No Indirectly No No
Night-time bowel movement / leakage Indirectly No No No Yes Yes Yes No Indirectly
Faecal incontinence Yes No No Yes Yes No Indirectly Yes No
Perianal fistula / discharge / pain No No No No No No Indirectly No No
Unintentional weight change Yes Yes No No No No No No No
Health-related QoL Yes Yes Yes Yes Yes Yes Yes Yes Yes
Fatigue and energy Yes Yes Yes Yes Yes Yes Yes Yes Yes
Emotional health Yes Yes Yes Yes Yes Yes Yes Yes Yes
Limitations to usual ADL No No No Yes Yes No Indirectly No Yes
Work/education productivity Yes No No Yes Yes No Yes Partially Yes
Psychometric properties by IBD-specific PROMs
Psychometric properties IBDQ SIBDQ IBDQ-9 UK-IBDQ CUCQ-32 CUCQ-8 IBD control RFIPC IBD-DI
Test–retest reliability  
[= reproducibility]
High High High High High High High High Med
Reliability – internal consistency Med Med Med Med High High High High High
Content validity High High High High High High High High High
Construct validity Med Med Med Med High High High High High
Responsiveness [ability to detect 
change]
Med Low Low Med Unknown Unknown High Low Unknown
*Outcomes preliminarily selected by Working Group for inclusion within the Symptoms, Function, and Quality of Life domain.
Table 4. The IBD Control Questionnaire42 [Questions 1–3].
1. Do you believe that:
 a. Your IBD has been well controlled in the past 2 weeks? Yes/No/Not sure
 b. Your current treatment is useful in controlling your IBD?
2. Over the past 2 weeks, have your bowel symptoms been getting worse, getting better or not changed? Better/No change/Worse
3. In the past 2 weeks, did you:
 a. Miss any planned activities because of IBD? [e.g. attending school/college, going to work or a social event]. Yes/No/Not sure
 b. Wake up at night because of symptoms of IBD? Yes/No/Not sure
 c. Suffer from significant pain or discomfort? Yes/No/Not sure
 d. Often feel lacking in energy [fatigued] [by “often” we mean more than half of the time]. Yes/No/Not sure
 e. Feel anxious or depressed because of your IBD? Yes/No/Not sure
 f. Think you needed a change to your treatment? Yes/No/Not sure
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a simple set of generic items applicable to all patients with IBD. It 
is freely available without a licence and takes less than 60 s to com-
plete, which gives it great potential in routine practice. Strong psy-
chometric properties have led to its selection for the UK IBD registry, 
although it is yet to be validated in other languages apart from 
Spanish. The Standard Set of outcomes defined here are designed for 
clinical practice and would only be adaptable to clinical trials once 
performance characteristics are defined by prospective measurement.
Parallel efforts to define PROMs in IBD have been driven by 
the CCFA within the USA, and the 10 most highly rated process 
and outcome measures were published in 2013.22 The current 
Working Group took advantage of this work by including key 
patient, association and clinical specialist representatives involved 
in the CCFA process. Similarly, the National Institutes of Health 
Patient-Reported Outcomes Measurement Information System met-
rics were developed for gastrointestinal symptoms in 2014.63 The 
development process and selected measures of both these initia-
tives reassuringly have much in common with ICHOM, but chal-
lenges remain with standardization of these measures. Strengths of 
the ICHOM Standard Set include international representation of 
patients and clinicians’ perspectives [including low-income coun-
tries], precise definitions of outcome measures and data sources for 
implementation, as well as recommended timelines for data collec-
tion. A minimum set of baseline characteristics [case-mix variables] 
has been determined to allow meaningful comparisons between 
populations via risk adjustment. The IBD Standard Set was further 
subject to patient validation surveys in several languages for global 
implementation and open review for comment by interested clini-
cians before finalization. Standard Sets remain open to modification 
by international agreement.
Nevertheless, the Standard Set has limitations. The patient num-
bers involved in focus groups and face-to-face interviews were few: 
however, unlike evidence-based science, the methodology of quali-
tative research and quality improvement depends not on numbers 
but on the extent to which concepts reflect the opinions of repre-
sentative groups. There is no standard for determining an adequate 
group size,64 and work in other fields has considered groups of 5–10 
patients to be optimal.39,65 Symptom domains of importance and 
concerns identified by our focus groups reflected those of earlier 
work by patient associations and others.23,40,41,66–68 Patient repre-
sentatives on the Working Group [MD, JM, HT, AW] present for the 
discussions and final decisions represented large patient organiza-
tions [CCFA, CCUK, and AFA]. More patients, groups and a wider 
validation survey might have been involved, but a balance had to be 
struck between resources and delivery within a 12 month time frame.
Despite the Working Group’s best efforts to develop consen-
sus definitions that were unambiguous, cultural characteristics and 
infrastructural differences will inevitably influence local data. For 
some measures, this meant that a broad definition had to be adopted. 
For example, although readmission and unexpected admission 
were identified as important outcomes for the domain Healthcare 
Utilization, the Working Group recognized the variation in thresh-
olds for admission that exists between healthcare providers. It there-
fore chose to measure total length of stay and separately to track ED 
visits. The Standard Set  also includes outcome measures that rely 
on pre-existing registry or administrative data. This is relevant for 
the Survival domain. Inaccurate or inconsistent information with 
respect to cause of death is well recognized. However, death is a 
central concern to patients, so could not reasonably be excluded as 
an outcome. The Working Group chose to include “unknown” as a 
response option for cause of death. Furthermore, not all outcome 
measures had practical definitions or validated tools available. This 
was the case for nutrition. Existing tools such as the Malnutrition 
Universal Screening Tool69 act as a screening tool for referral [process 
Table 5. ICHOM Standard Set for Inflammatory Bowel Disease: case-mix and treatment variables.
Patient population Measure Supporting ionformation Timing Suggested data sources
Demographics
All patients Year of birth N/A Baseline Patient-reported
Male or female
Education level Highest level of schooling completed using 
the International Standard Classification of 
Education
Smoking status [of cigarettes, cigars or tobacco] Baseline and 
annual follow-up
Patient height To calculate BMI Baseline
Patient weight
Baseline clinical factors
All patients Comorbidities including  
autoimmune conditions
N/A Baseline and 
annual follow-up
Patient-reported
Previous infection HIV, HBV or TB
Baseline condition factors
All patients Diagnosis Crohn’s disease, ulcerative colitis,  
indeterminate IBD or colitis unclassified
Baseline Clinician-reported
Date of diagnosis N/A
Disease phenotype Tracked via Montreal Classification
Presence of extra-intestinal 
manifestations
Eye, skin, joint, hepatobiliary or other Baseline and 
annual follow-up
Treatment factors
Surgical patients Type of IBD-related surgery Including method of surgical procedure, date 
of surgery, and type of colectomy
Baseline and 
annual follow-up
Clinician-reported
Medical patients Current medication N/A
Patients diagnosed with 
colorectal cancer
Participation in a colo-
rectal cancer surveillance 
programme
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measure] rather than monitoring. Tools requiring anthropometrics 
or incorporating biochemical measures were considered impractical. 
The Working Group chose to measure height and weight at base-
line for BMI calculation and then change in weight as a surrogate 
marker of nutritional status and an outcome of care, because this is 
a universally available, objective measure in low-income countries 
where access to more costly assessments may be difficult. We used 
a modified two-round Delphi process to reach consensus on each 
of the selected outcome measures, and case-mix variables including 
“how” and “when” these should be captured. The level of consen-
sus deemed necessary in the Delphi process remains ambiguous in 
the literature, and there are no agreed norms for size of consensus, 
with practice varying from basic majority to more stringent propor-
tions. The level of agreement used in our work was pragmatic, based 
on other successfully conducted international consensus processes 
for outcomes, including those used by ICHOM in other published 
Standard Sets. Notably, the Core Outcome Measures in Effectiveness 
Trials initiative used this cut-off.70 The minimum denominator for all 
votes was 17, representing 77–81% of the Working Group members 
[excluding the Project Team]. It should be noted that while numbers 
formally participating in any given vote varied, all Working Group 
members were subsequently prompted for feedback and had the 
opportunity to confirm or challenge the results. The final Standard 
Set was approved unanimously by the Working Group.
This international, multidisciplinary IBD Working Group has 
developed a minimum set of patient-centred outcomes, tools and 
PROMs for collection in patients with IBD. Data collection needs to 
be piloted and a standardized collection platform developed before 
data quality and outcomes can be compared in different settings. 
ICHOM is committed to facilitating broad adoption of this set and 
has made the full recommendations freely available on its website 
[www.ichom.org/medical-conditions/inflammatory-bowel-disease], 
along with a reference guide to assist with technical aspects of imple-
mentation. The near-term goal will be to implement the set and to 
use this as a proof of concept towards broader adoption or endorse-
ment by payors and governments. A steering committee will oversee 
revisions to the Standard Set to reflect changes in data collection 
capacity, to clarify outcome or baseline characteristics definitions 
as needed and respond to improvements in outcome measurement 
tools. In this way, the international IBD community can move 
towards the ultimate goal of acquiring internationally comparable 
data on patient-centred outcomes and improve the value of care.
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